Literature DB >> 35693374

Hemorrhagic Lesions in the Central Nervous System: Toxoplasmosis in a Person Living With Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome.

Navneet Arora1, Sejal Kotwani1, Manika Chhabra2, Mohan H1.   

Abstract

Central nervous system (CNS) toxoplasmosis is one of the common causes of hemorrhagic brain lesions in people living with HIV and AIDS (PLWHA), resulting in high mortality and morbidity. It has a broad clinical and neuro-radiological spectrum, which may or may not be limited to typical findings of focal and subacute neurological deficits or ring-enhancing lesions in the basal ganglia. Here, we present a case of a patient who is a newly detected person living with HIV and AIDS with a low CD4 cell count and classical imaging findings of central nervous system toxoplasmosis on his magnetic resonance imaging (MRI) of the brain. The incidence of opportunistic infections has been reduced after introducing highly active antiretroviral therapy (HAART); this case will be helpful to clinicians in identifying CNS toxoplasmosis as it has classical imaging findings on the MRI brain.
Copyright © 2022, Arora et al.

Entities:  

Keywords:  cd4 cell; opportunistic infection; person living with hiv/aids (plha); susceptibility-weighted images; toxoplasmosis

Year:  2022        PMID: 35693374      PMCID: PMC9173227          DOI: 10.7759/cureus.24827

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  9 in total

Review 1.  Focal neurological disease in patients with acquired immunodeficiency syndrome.

Authors:  Daniel J Skiest
Journal:  Clin Infect Dis       Date:  2002-01-01       Impact factor: 9.079

2.  Best cases from the AFIP: cerebral toxoplasmosis.

Authors:  Gregory Tse Lee; Fernando Antelo; Anton A Mlikotic
Journal:  Radiographics       Date:  2009 Jul-Aug       Impact factor: 5.333

3.  Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.

Authors:  Andrea Antinori; Dora Larussa; Antonella Cingolani; Patrizia Lorenzini; Simona Bossolasco; Maria Grazia Finazzi; Marco Bongiovanni; Giovanni Guaraldi; Susanna Grisetti; Beniamino Vigo; Beniamino Gigli; Andrea Mariano; Ernesto Renato Dalle Nogare; Michele De Marco; Francesca Moretti; Paola Corsi; Nicola Abrescia; Patrizia Rellecati; Antonella Castagna; Cristina Mussini; Adriana Ammassari; Paola Cinque; Antonella d'Arminio Monforte
Journal:  Clin Infect Dis       Date:  2004-11-05       Impact factor: 9.079

4.  Toxoplasmosis with early intracerebral hemorrhage in a patient with the acquired immunodeficiency syndrome.

Authors:  P Trenkwalder; C Trenkwalder; W Feiden; T J Vogl; K M Einhäupl; H Lydtin
Journal:  Neurology       Date:  1992-02       Impact factor: 9.910

5.  Primary central nervous system lymphoma: CT and pathologic correlation.

Authors:  Y Y Lee; J M Bruner; P Van Tassel; H I Libshitz
Journal:  AJR Am J Roentgenol       Date:  1986-10       Impact factor: 3.959

Review 6.  From the archives of the AFIP: central nervous system infections associated with human immunodeficiency virus infection: radiologic-pathologic correlation.

Authors:  Alice B Smith; James G Smirniotopoulos; Elisabeth J Rushing
Journal:  Radiographics       Date:  2008 Nov-Dec       Impact factor: 5.333

Review 7.  Advances and Challenges in Understanding Cerebral Toxoplasmosis.

Authors:  Dirk Schlüter; Antonio Barragan
Journal:  Front Immunol       Date:  2019-02-14       Impact factor: 7.561

Review 8.  HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease.

Authors:  José Ernesto Vidal
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

9.  Imaging features of neurotoxoplasmosis: A multiparametric approach, with emphasis on susceptibility-weighted imaging.

Authors:  John C Benson; Gustavo Cervantes; Thomas R Baron; Andrew E Tyan; Siobhan Flanagan; Leandro T Lucato; Alexander M McKinney; Frederick Ott
Journal:  Eur J Radiol Open       Date:  2018-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.